Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1980 2
1981 1
1982 1
1983 2
1985 1
1988 4
1989 2
1991 2
1992 3
1993 2
1994 4
1995 1
1996 2
1998 2
1999 3
2001 2
2002 3
2003 2
2004 4
2005 3
2006 13
2007 15
2008 10
2009 18
2010 19
2011 13
2012 12
2013 11
2014 14
2015 18
2016 13
2017 19
2018 18
2019 27
2020 39
2021 39
2022 39
2023 31
2024 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Results by year

Filters applied: . Clear all
Page 1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
cGAS-STING signaling pathway in intestinal homeostasis and diseases.
Yang Y, Wang L, Peugnet-González I, Parada-Venegas D, Dijkstra G, Faber KN. Yang Y, et al. Among authors: dijkstra g. Front Immunol. 2023 Sep 14;14:1239142. doi: 10.3389/fimmu.2023.1239142. eCollection 2023. Front Immunol. 2023. PMID: 37781354 Free PMC article. Review.
The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, van Goor H, Mann GE, Dijkstra G, Faber KN. Geertsema S, et al. Among authors: dijkstra g. Trends Mol Med. 2023 Oct;29(10):830-842. doi: 10.1016/j.molmed.2023.07.008. Epub 2023 Aug 7. Trends Mol Med. 2023. PMID: 37558549 Review.
Proton pump inhibitors affect the gut microbiome.
Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. Imhann F, et al. Among authors: dijkstra g. Gut. 2016 May;65(5):740-8. doi: 10.1136/gutjnl-2015-310376. Epub 2015 Dec 9. Gut. 2016. PMID: 26657899 Free PMC article.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.
Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK. Vich Vila A, et al. Among authors: dijkstra g. Sci Transl Med. 2018 Dec 19;10(472):eaap8914. doi: 10.1126/scitranslmed.aap8914. Sci Transl Med. 2018. PMID: 30567928
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.
380 results